Biomarkers in AKI With Cardiorenal Syndrome
Biomarkers in AKI With Cardiorenal Syndrome
Within the next few years, the burgeoning field of biomarkers for diagnosis of AKI, particularly in the setting of CRS, will be more advanced and ready for clinical application. Countless studies are currently underway to confirm the clinical utility of the biomarkers reviewed here, as well as many others. Several of the novel markers covered will most likely be in clinical practice and possibly even part of standard of care for AKI. NGAL seems the most likely to enter standard clinical care first as it has the most extensive and promising body of research thus far; however, other markers such as NAG and KIM-1 may not be far behind. The main limitation of these biomarkers is their cost and the accessibility to the laboratory platforms required for their analysis, and it is unclear how they will impact clinical outcomes as these large studies have yet to be conducted. However, based on the current data, these biomarkers appear to have promise to help with the management of AKI and CRS.
Expert Commentary & Five-Year View
Within the next few years, the burgeoning field of biomarkers for diagnosis of AKI, particularly in the setting of CRS, will be more advanced and ready for clinical application. Countless studies are currently underway to confirm the clinical utility of the biomarkers reviewed here, as well as many others. Several of the novel markers covered will most likely be in clinical practice and possibly even part of standard of care for AKI. NGAL seems the most likely to enter standard clinical care first as it has the most extensive and promising body of research thus far; however, other markers such as NAG and KIM-1 may not be far behind. The main limitation of these biomarkers is their cost and the accessibility to the laboratory platforms required for their analysis, and it is unclear how they will impact clinical outcomes as these large studies have yet to be conducted. However, based on the current data, these biomarkers appear to have promise to help with the management of AKI and CRS.
Source...